Structure−Activity Relationships in Platelet-Activating Factor. 12. Synthesis and Biological Evaluation of Platelet-Activating Factor Antagonists with Anti-HIV-1 Activity

Authors:
  • MMMarc Martin
    Marc Martin
  • OBOkkacha Bensaid
    Okkacha Bensaid
  • CRChristophe Rousselle
    Christophe Rousselle
  • NDNathalie Dereuddre-Bosquet
    Nathalie Dereuddre-Bosquet
  • JHJack Huet
    Jack Huet
  • CRCatherine Redeuilh
    Catherine Redeuilh
  • ALAazdine Lamouri
    Aazdine Lamouri
  • CDChang-Zhi Dong
    Chang-Zhi Dong
  • PCPascal Clayette
    Pascal Clayette
  • JSJean-Michel Scherrmann
    Jean-Michel Scherrmann

Abstract
The HIV-1 central nervous system infection leads to the onset of neurological impairments called AIDS dementia complex (ADC). PAF plays an important role in this pathology, as it is an HIV-1-induced neurotoxin produced by infected or activated macrophages and microglia, in the brain. We previously reported that PAF-antagonists bearing a trisubstituted piperazine presented in vitro anti-HIV-1 activity in human macrophages. To improve the pharmacological activities of our lead compound, 1a, we modified its carbamate function and evaluated both its antiretroviral and anti-PAF activities. One carbamate derivative (10c) demonstrated a similar antiviral activity but a higher anti-PAF potency, whereas 4a, with an ureide function, presents an increased antiviral activity and can be considered as a pure antiretroviral drug, as it does not present PAF-antagonism. Moreover, we measured the ability of 1a to cross the blood−brain barrier, using the in situ mouse brain perfusion method and its plasmatic concentrations after iv and po administration. The transport parameter measured (Kin) proves that 1a is able to cross this biological barrier, but a pharmacokinetic study reveals its weak bioavailability in rats.

This publication has 13 references indexed in Scilit: